Psoriasis: secukinumab vs ustekinumab in a real-world study

  • López Jiménez P & al.
  • Dermatol Ther
  • 15 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A small real-world study provides insight into the relative efficacy of secukinumab (Cosentyx) vs ustekinumab (Stelara) in patients with moderate to severe psoriasis.

Why this matters

  • Several biologic treatments are now available for psoriasis, which necessitates comparative studies in regular clinical practice.

Key results

  • At week 52, patients treated with secukinumab were more likely to achieve ≥90% improvement in the Psoriasis Area and Severity Index (PASI 90) compared with patients treated with ustekinumab (82.75% vs 43.33%; P=.002).
  • PASI75 response was not statistically different between groups (89.65% vs 73.33%, P=.108).
  • The most common adverse events were upper respiratory tract infections (6.9% for secukinumab, 6.7% for ustekinumab) and headache of low/mild severity (6.9% for secukinumab, 10% for ustekinumab).

Study design

  • 59 patients with psoriasis, 29 treated with secukinumab and 30 with ustekinumab, were analyzed for skin clearance.
  • Funding: None disclosed.

Limitations

  • Small patient sample size.
  • Retrospective study.